May 7, 2020 / 9:33 PM / a month ago

BRIEF-Revance Reports First Quarter 2020 Financial Results, Provides Corporate Update

May 7 (Reuters) - Revance Therapeutics Inc:

* REVANCE REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS, PROVIDES CORPORATE UPDATE

* REVANCE THERAPEUTICS INC - ON SCHEDULE FOR Q2 2020 READOUTS FROM ITS FOREHEAD LINES AND CROW’S FEET OPEN-LABEL PHASE 2 STUDIES

* REVANCE THERAPEUTICS INC - COVID-19 HAS, HOWEVER, CAUSED CO TO ADJUST LAUNCH OF ITS RHA DERMAL FILLER LINE

* REVANCE THERAPEUTICS - ANNOUNCED A PAUSE IN ENROLLMENT OF REVANCE’S JUNIPER PHASE 2 TRIAL FOR ADULT UPPER LIMB SPASTICITY

* REVANCE THERAPEUTICS INC - REVENUE FOR QUARTER ENDED MARCH 31, 2020 WAS $58 THOUSAND COMPARED TO $278 THOUSAND FOR SAME PERIOD IN 2019

* REVANCE THERAPEUTICS - EXPECTS 2020 U.S. GAAP OPERATING EXPENSE TO BE AT LOWER END OF RANGE OF $270 TO $280 MILLION

* REVANCE THERAPEUTICS INC - EXPECTS 2020 NON-GAAP OPERATING EXPENSE TO BE AT LOWER END OF RANGE OF $220 TO $230 MILLION

* REVANCE THERAPEUTICS INC - WITH CURRENT CASH AND EQUIVALENTS, MANAGEMENT PROJECTS THAT COMPANY IS FUNDED INTO 2023 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below